Thorax

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
Thorax 2006;61:831; doi:10.1136/thx.2006.awoct06
Copyright © 2006 BMJ Publishing Group Ltd & British Thoracic Society
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wedzicha, W.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Wedzicha, W.
Topic Collections
Right arrowRelated Articles

Airwaves

Wisia Wedzicha, Editor in Chief

The first 150 words of the full text of this article appear below.


LONG TERM MACROLIDES IN CF
There has been increasing interest in the anti-inflammatory effects of macrolide antibiotics and they have now been studied in a number of conditions. A large trial of the macrolide azithromycin taken over 6 months showed benefit in adult patients with cystic fibrosis (CF) colonised with Pseudomonas aeruginosa, but it is not clear if macrolides are beneficial in younger CF patients. In this issue of Thorax, Clement and colleagues describe a randomised controlled trial of azithromycin given for 3 days per week to CF patients (age 6–21 years) and followed for 12 months. The authors report that azithromycin reduced the number of exacerbations, the time to the first exacerbation, and the number of additional courses of antibiotics, regardless of whether or not they were infected with P aeruginosa. This trial shows that the beneficial effect of azithromycin can be observed at an earlier stage of lung disease and . . . [Full text of this article]


Related Articles

Caring for the burden of COPD
P M A Calverley
Thorax 2006 61: 831-832. [Extract] [Full Text] [PDF]

Spirometric screening: does it work?
D M Mannino
Thorax 2006 61: 834-835. [Extract] [Full Text] [PDF]

UK National COPD Audit 2003: impact of hospital resources and organisation of care on patient outcome following admission for acute COPD exacerbation
L C Price, D Lowe, H S R Hosker, K Anstey, M G Pearson, C M Roberts on behalf of the British Thoracic Society and the Royal College of Physicians Clinical Effectiveness Evaluation Unit (CEEu)
Thorax 2006 61: 837-842. [Abstract] [Full Text] [PDF]

Admissions to hospital with exacerbations of chronic obstructive pulmonary disease: effect of age related factors and service organisation
M J Connolly, D Lowe, K Anstey, H S R Hosker, M G Pearson, C M Roberts on behalf of the British Thoracic Society and the Royal College of Physicians Clinical Effectiveness Evaluation Unit (CEEu)
Thorax 2006 61: 843-848. [Abstract] [Full Text] [PDF]

Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas
J-Y Wang, P-R Hsueh, I-S Jan, L-N Lee, Y-S Liaw, P-C Yang, and K-T Luh
Thorax 2006 61: 903-908. [Abstract] [Full Text] [PDF]

Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial
A Clement, A Tamalet, E Leroux, S Ravilly, B Fauroux, and J-P Jais
Thorax 2006 61: 895-902. [Abstract] [Full Text] [PDF]

Smokers with airway obstruction are more likely to quit smoking
M Bednarek, D Gorecka, J Wielgomas, M Czajkowska-Malinowska, J Regula, G Mieszko-Filipczyk, M Jasionowicz, R Bijata-Bronisz, M Lempicka-Jastrzebska, M Czajkowski, G Przybylski, and J Zielinski
Thorax 2006 61: 869-873. [Abstract] [Full Text] [PDF]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2006 BMJ Publishing Group Ltd & British Thoracic Society